TOS Spring Summit

Session Opening

Jen-Shi Chen (陳仁熙), MD

Introduction of the ATLAS Network

Speaker: Mitsumi Terada, PhD, National Cancer Center Hospital

Chair: Tom Wei-Wu Chen(陳偉武), MD, PhD, National Taiwan University Hospital

Enhancing Academic Oncology Trials in Taiwan: Experiences Collaborating with TCOG

Speaker: Nai-Jung Chiang (姜乃榕), MD, PhD, Taipei Veterans General Hospital

Chair: Tai-Lung Cha(查岱龍), PhD, Tri-Service General Hospital

Coffee Break & Networking

Oncology Capability Expanded Through Sponsored Clinicals in Malaysia

Speaker: Akhmal Yusof, MD, Clinical Research Malaysia

Chair: Ann-Lii Cheng (鄭安理), MD, PhD, National Taiwan University Cancer Center Hospital

Overview of Clinical Trials in Taiwan (TBC)

Speaker: Shu-Han Chang (張淑涵), MD, Taiwan Food and Drug Administration

Chair: Jen-Shi Chen (陳仁熙), MD, Linkou Chang Gung Memorial Hospital

Panel Discussion (All Speakers)

Session Closing

Jen-Shi Chen (陳仁熙), MD

#HanchorBio

Reprogramming the CD47–SIRPα Axis in Cancer Immunotherapy: Clinical Validation and Next-Generation Multi-Checkpoint Engineering

Speaker: Alvin LUK (陸英明), PhD, HanchorBio Inc.

Chair: Peter Mu-Hsin Chang (張牧新), MD, PhD, Taipei Veterans General Hospital

Session Opening

John Wen-Cheng Chang (張文震), MD

Latest Updates on CTLA-4 Blockade and Emerging Combination Strategies

Speaker: Paolo Antonio Ascierto, MD, Department of Skin Cancers, Cancer Immunotherapy and Development Therapeutics Istituto Nazionale Tumori IRCCS-Fondazione Pascale, Napoli, Italy

Chair: John Wen-Cheng Chang (張文震), MD, Linkou Chang Gung Memorial Hospital

AIDeN (Adaptive Immune Defensive Network): A large Model for Adaptive immunity

Speaker: Jian Han, MD, iRepertoire & iCubate

Chair: Yung-Chang Lin (林永昌), MD, Linkou Chang Gung Memorial Hospital

Co-Chairs: Joe Yeong, Peter Chiao-En Wu

Mentors: Michael Lotze, James Gulley, Barbara Seliger, Paolo Antonio Ascierto, John Chang, Jian Han, etc.

Participating Societies: Hong Kong Cancer Therapy Society (HKCTS), Immuno-Oncology Society of India (I-OSI), Japanese Association of Cancer Immunology (JACI), Korean Society of Medical Oncology (KSMO), Malaysian Society for Biochemistry & Molecular Biology (MSBMB), Singapore Society of Oncology - Cancer Immunotherapy Consortium (SSO-CIC), Taiwan Society for Immunotherapy of Cancer (TSITC), Taiwan Oncology Society (TOS), Thailand Hub of Talent for Cancer Immunotherapy (TTCI), TransMed-Vietnam

Session Opening & Introduction

HKCTS

(OP-01) Immunotherapy in ERBB2-Mutant NSCLC: Efficacy and PD-L1 Association in a Real-World Cohort from Hong Kong

Qijun Du, Department of Clinical Oncology, Pamela Youde Nethersole Eastern Hospital

TOS

(OP-02) The Immune Modulation Effects of Ovarian Function Suppression in Premenopausal Patients with Hormone Receptor-Positive Breast Cancer

Zola Chia-Chen Li, National Taiwan University Cancer Center

I-OSI

(OP-03) Novel Humanized Anti-CD20 CAR-T Cells with Improved Metabolic Fitness Show Superior in Vivo Efficacy in B-Cell Lymphoma: A Promising Candidate for CD19/CD20 Dual CAR-T Strategies

Ambalika Chowdhury, Indian Institute of Technology Bombay

MSBMB

(OP-04) Enhancing Immune Surveillance in Head and Neck Cancer with DNA Vaccine

Chai Phei Gan, Cancer Research Malaysia

TransMed-VN

(OP-05) Engineering Human iPSC-Derived NK Cells with CAR19 and IL-18 for Targeted Immunotherapy of ALL

Son Vu, Vinmec-VinUni Institute of Immunology, College of Health Sciences, VinUniversity

TTCI

(OP-06) Generation of Dual Bispecific Protein Engagers Targeting Mesothelin and NECTIN2 for Activation of Cytotoxic T-Lymphocytes Against Colorectal Cancer Cells

Suyanee Thongchot, Mahidol University

SSO-CIC

(OP-07) Some Tumours Are ‘Born Bad’: Baseline TME Predicts Relapse in EGFR-Mutant Never-Smoker NSCLC

Komal Gupta, National Cancer Center Singapore

TSITC

(OP-08) Spatial Multiomics Identifies EGFR Mutation-Associated Vasculogenic Mimicry Signatures and Distinct Immune Spatial Architectures in Lung Adenocarcinoma

Chun-Hui Lee, National Cheng Kung University Hospital

JACI

(OP-09) Spatial Transcriptomic Analysis Reveals Spatially Organized Macrophage–Fibroblast Crosstalk Driving Immune Exclusion in Urothelial Carcinoma

Tomohiro Iwasawa, Department of Urology, Keio University School of Medicine

KSMO

(OP-10) Lactic Acid Bacteria Enhance Antitumor Immunity in Bladder Cancer via Modulation of the Tumor Microenvironment

Hyun Jin Bang, Chonnam National University Hwasun Hospital

YI Poster Viewing (Authors Present) at 11th Floor Poster Area

TOS

(PP-05) Prediction of anti-PD1 Immunotherapy Efficacy in Head-Neck Squamous Cell Carcinoma Through Digital Pathology Artificial Intelligence

Tien Hua Chen, Taipei Veterans General Hospital

SSO-CIC

(PP-06) H&E 3.0: An AI-Driven, Chemical-Free Virtual Histology Solution Enabling Worldwide Multiomics Profiling

Ruisi Li, Agency for Science, Technology and Research (A*STAR)

TSITC

(PP-07) A Mutant KRAS-Specific GM-CSF-Armed Oncolytic Adenovirus Exerts Tumoricidal Effects on Pancreatic Adenocarcinoma via a Favorable Antitumor Microenvironment

Po-Shen Ko, Taipei Veterans General Hospital/National Yang Ming Chiao Tung University

JACI

(PP-08) Live FluoroSpot: Real-Time Visualization of CTL-Mediated Cytotoxicity at Single-Cell Resolution

Zhuohao Yang, The University of Tokyo